Obexelimab marketing applications for the treatment of IgG4-RD expected to be submitted to the FDA in Q2 2026 and the EMA in H2 2026 based on the Phase 3 INDIGO trial results - - Topline results of ...
People with psoriasis prescribed bimekizumab have no greater risk for major depressive disorder or suicidal ideation than ...
UCB said it’s the first time an approved biologic demonstrated superiority over an IL-23 blocker in psoriatic arthritis. Yet analysts aren’t sure how commercially impactful the results will be.
Opinion
Congressman Sorensen Fights for Corn Growers and Lower Gas Prices with the Sale of Year-Round E-15
This week, Congressman Eric Sorensen (IL-17) introduced an amendment to the farm bill that would permit the year-round, nationwide sale of E-15. This change in policy would expand access to markets ...
As IL-6 inhibition comes into practice for PMR, research advances on other therapeutic mechanisms of action, from IL-17 to ...
Stay informed with the latest Germany news and stories. Explore match reports, club updates and transfers rumours with GOAL ...
2don MSN
IL 17th Congressional District, Rock Island sheriff race and more: News 8 this week - March 15, 2026
News 8 This Week previews the 17th Congressional District race, Rock Island County sheriff primary, local tax questions and ...
A simulated analysis in psoriasis highlights divergent patient and payer incentives and inconsistent coverage strategies behind barriers to phototherapy uptake.
The latest announcement is out from Zura Bio ( (ZURA) ).
Stay informed with the latest Qarabag FK news and stories. Explore match reports, club updates and transfers rumours with GOAL ...
MedPage Today on MSN
Bimekizumab Safety Holds Up in Long-Term Data
Pooled data from PsA and axSpA extension studies provide early reassurance ...
Barclays 28th Annual Global Healthcare Conference March 12, 2026 11:30 AM EDTCompany ParticipantsDinesh Patel - ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results